Medine.co.uk

Alateris 625mg Tablets

Informations for option: Alateris 625mg Tablets, show other option
Document: leaflet MAH BRAND_PLPI 20774-1348 change

Alateris® 625 mg tablets

Glucosamine hydrochloride

Read all of this leaflet carefully before you start taking this medicine.

•    Keep this leaflet. You may need to read it again.

•    If you have further questions, please ask your doctor or your pharmacist.

•    This medicine has been prescribed for you personally and you should not pass it on to others. It may harm them, even if their symptoms are the same as yours.

•    If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

The name of your medicine is Alateris 625mg tablets, but will be referred to as Alateris throughout the remainder of the leaflet.

In this leaflet:

1.    What Alateris is and what it is used for

2.    Before you take Alateris

3.    How to take Alateris

4.    Possible side effects

5.    How to store Alateris

6.    Further information

1.    What Alateris is and what it is used for

Alateris belongs to the group of medicines called anti-inflammatory and anti-rheumatic agents, non-steroids.

Alateris is used for the relief of symptoms in mild to moderate osteoarthritis of the knee.

2.    Before you take Alateris

Do not take Alateris if you:

•    are allergic (hypersensitive) to glucosamine or to any of the other ingredients of Alateris.

•    are allergic (hypersensitive) to shellfish, since glucosamine is manufactured from shellfish.

Take special care with Alateris (and speak to your doctor) if you:

•    suffer from impaired glucose tolerance.

More frequent controls of your blood glucose levels may be necessary when starting treatment with Alateris.

•    have impaired kidney or liver function.

•    have a known risk factor for cardiovascular (heart) disease, since an abnormally high level of cholesterol in the blood has been observed in a few patients treated with Alateris.

•    suffer from asthma. When starting on Alateris, you should be aware of potential worsening of symptoms.

Alateris should not be used in children and adolescents below the age of 18 years.

You should stop taking Alateris and see your doctor immediately if you experience symptoms of angioedema, such as

•    swollen face, tongue or throat

•    difficulty to swallow

•    hives and difficulties to breathe

Taking other medicines

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

Caution should be exercised if Alateris has to be combined with other medicines, especially:

•    warfarin

•    tetracycline

Increased effect of coumarin anticoagulants (e.g. warfarin) during concomitant treatment with glucosamine has been reported. Patients treated with such combinations should therefore be monitored extra carefully when initiating or ending glucosamine therapy.

Please contact your doctor for medical advice.

Taking Alateris with food and drink

You can take the tablets with or without food and they should be swallowed together with some water or other suitable liquid.

Pregnancy and breast-feeding

Alateris should not be used during pregnancy. The use of Alateris during breast-feeding is not recommended. Ask your doctor or pharmacist for advice before taking any medicine.

(leaflet continued overleaf)


(leaflet continued)

Driving and using machines

No studies on the effects on the ability to drive and use machines have been performed. If you experience dizziness or drowsiness from the tablets, you should not drive or operate machinery.

3.    How to take Alateris Dosage

Always take Alateris exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.

The usual starting dose is 2 tablets (1250 mg of glucosamine) once daily, taken orally.

Glucosamine is not indicated for the treatment of acute painful symptoms. Relief of symptoms (especially pain relief) may not be experienced until after several weeks of treatment and in some cases even longer. If no relief of symptoms is experienced after 2-3 months, continued treatment with Alateris should be reevaluated.

The tablets should be swallowed together with some water or other suitable liquid.

If you take more Alateris than you should

If you have taken large quantities you must consult your doctor or a hospital. Signs and symptoms of overdose with glucosamine might include headache, dizziness, confusion, joint pain, feeling sick, vomiting (being sick), diarrhoea or constipation. Stop taking glucosamine at signs of overdose.

If you forget to take Alateris

Do not take a double dose to make up for a forgotten dose. If it is almost time for your next dose, skip the forgotten dose and carry on taking Alateris as scheduled.

If you stop taking Alateris

Your symptoms may reoccur.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4.    Possible side effects

Like all medicines, Alateris can cause side effects, although not everybody gets them.

The following have been reported:

Common (affects 1 to 10 users in 100):

headache, tiredness, feeling sick, abdominal pain, indigestion, diarrhoea, constipation.

Uncommon (affects 1 to 10 users in 1000):

rash, itching, flushing.

Not known (frequency cannot be estimated from the available data):

Swelling of face, tongue, or throat (angioedema, see Take special care with Alateris), hives, swelling/swelling of ankles, legs and feet, dizziness, vomiting (being sick), blood glucose control worsened in patients with diabetes mellitus, hepatic enzyme elevation, jaundice.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.qov.uk/vellowcard.

By reporting side effects, you can help provide more information on the safety of this medicine.

5.    How to store Alateris

Keep out of the sight and reach of children.

Do not use Alateris after the expiry date which is stated on the blister/carton or tablet container.

Store in the original package in order to protect from moisture. Do not store above 30"C. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

6.    Further information

What Alateris tablets contains

Alateris is a white to light beige, oval tablet marked with “G” on one side and a score line on the other. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

Each tablet contains 625 mg of glucosamine (as glucosamine hydrochloride).

Also contains microcrystalline cellulose, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose (L-HPC) and magnesium stearate.

Alateris are available in packs size of 60 tablets.

Manufactured by: Weifa AS, Hausmannsgate 6, P.O. box 9113, Grunolandia 0133 Oslo, Norway or Haupt Pharma Wulfing GmbH, Bethelner Landstr. 18, 31028 Gronau, Germany. Procured from within the EU. Product Licence holder: Quadrant Pharmaceuticals Ltd, Lynstock House, LynstockWay, Lostock, Bolton BL6 4SA. Repackaged by Maxearn Ltd, Bolton BL6 4SA.

PL 20774/1348 Alateris 625mg tablets

POM


Date of revision: 29th April 2015

Alateris is registered trademark of Laboratoires Expanscience